A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis.
Phase of Trial: Phase III
Latest Information Update: 17 Apr 2017
At a glance
- Drugs Infliximab (Primary) ; Methotrexate
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- Acronyms DOSE
- Sponsors Merck Sharp & Dohme
- 29 Jun 2012 Companies added in the association field as reported by EudraCT.
- 28 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Nov 2010 Planned End Date changed from 1 Feb 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov.